---
title: "MIRA Pharmaceuticals, Inc. (MIRA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MIRA.US.md"
symbol: "MIRA.US"
name: "MIRA Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T11:55:12.991Z"
locales:
  - [en](https://longbridge.com/en/quote/MIRA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MIRA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MIRA.US.md)
---

# MIRA Pharmaceuticals, Inc. (MIRA.US)

## Company Overview

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [mirapharmaceuticals.com](https://mirapharmaceuticals.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.30 | 114 | - | - | - |
| PB | 4.35 | 138 | 44.17 | 8.76 | 6.43 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-18T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.97 |
| Highest Target | 17.75 |
| Lowest Target | 17.75 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MIRA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MIRA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MIRA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MIRA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**